Skip to main content

Table 1 Clinical characteristics of 147 patients

From: Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma

Clinical characteristics

Proportion (%)

Gender

 

Male

60.5 (89/147)

Female

39.5 (58/147)

Subtype

 

IgG

48.3 (71/147)

IgA

24.5 (36/147)

IgD

6.1 (9/147)

IgE

0.7 (1/147)

κ light chain

11.6 (17/147)

λ light chain

8.8 (13/147)

DS stage

 

I

4.1 (6/147)

II

13.6 (20/147)

III

82.3 (121/147)

ISS stage

 

I

15.6 (23/147)

II

32.0 (47/147)

III

52.4 (77/147)

R-ISS stage*

 

I

13.0 (18/138)

II

64.5 (89/138)

III

22.6 (31/138)

1q21*

 

Gain

25.7 (35/136)

Amplification

24.3 (33/136)

High-risk karyotype*

 

del(17p)

12.5 (17/136)

t(4; 14)

17.6 (24/136)

t(14; 16)

0.7 (1/136)

Anemia†

64.6 (95/147)

Renal insufficiency‡

31.3 (46/147)

Extramedullary disease

20.4 (30/147)

Induction therapy regimen

 

PIs-based

50.3 (74/147)

IMiDs-based

9.5 (14/147)

PIs + IMiDs

38.1 (56/147)

Completed ASCT

25.9 (38/147)

  1. ISS International Staging System, PIs proteasome inhibitors, IMiDs immunomodulatory drugs, ASCT autologous hematopoietic stem cell transplantation
  2. *Some patients did not undergo the FISH examinations, so the proportions are calculated by the numbers of patients with FISH results
  3. †Anemia refers to hemoglobin < 100 g/L
  4. ‡Renal insufficiency refers to creatinine > 177 µmol/L or creatinine clearance < 40 ml/min
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us